KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial.

Brigida A Maiorano, Matthew R Smith, Maha Hussain, Fred Saad, Bertrand Tombal, Cora N Sternberg, Ateesha F Mohamed, Manjari Dissanayake, Marius Moscovici, Frank Verholen, Iris Kuss, Karim Fizazi

Eur J Cancer 248 117764

PMID42892235
PMCID-
DOI10.1016/j.ejca.2026.117764
发表日期2026-10-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: To identify patients likely to benefit from intensified darolutamide treatment while minimizing adverse events (AEs), this analysis applied quality-adjusted time without symptoms or toxicity (Q-TWiST) to evaluate quality-adjusted survival in metastatic hormone-sensitive prostate cancer in ARASENS, comparing triplet therapy (darolutamide + androgen deprivation therapy [ADT] + docetaxel) with placebo doublet therapy (ADT + docetaxel). METHODS: Time with toxicity (TOX; with grade 3/4 symptoms/toxic effects), time without symptoms or toxicity (TWiST), and time in relapse/disease progression (REL) were estimated using 53-month restricted means based on grade 3/4 AEs, time to metastatic castration-resistant prostate cancer, and overall survival ARASENS data. Q-TWiST was calculated as the utility-weighted sum of time spent in each health state per treatment arm. RESULTS: Patients gained an additional 6.3 months of Q-TWiST with darolutamide versus placebo (p < 0.001) driven by increased TWiST (mean 17.6 months vs 10.9 months), and decreased REL (2.4 months vs 8.7 months). Longer treatment resulted in more TOX (17.2 months vs 11.3 months) at 53 months. Partitioned Kaplan-Meier survival curves showed sustained TWiST with darolutamide versus placebo over 53 months. Relative Q-TWiST gain was 16.0% (clearly clinically important). CONCLUSION: Darolutamide triplet therapy offers longer survival benefits without symptoms or toxicity versus placebo, aiding evaluation of efficacy-tolerability balance and supporting patient-centered decision-making.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。